New treatment for HIV could mean dosing patients only once a year

Written by Lucy Chard (Future Science Group)

HIV nanocrystal prodrug annual treatment

A research team from the University of Nebraska Medical Center (UNMC; NE, USA) led by Benson Edagwa (Assistant Professor) and Howard Gendelman (Chairman and Professor) have developed a novel therapeutic for the prevention of HIV infection. The team have discovered a way to adminsister antiretrovirals (ARVs) that patients take daily to control the disease, to just a once-a-year vaccine dose instead. “This pharmaceutical development has the potential to not only treat but also prevent viral transmission,” stated Gendelman. “This may certainly be a therapeutic milestone.” The year-long acting drug is based on the existing drug cabotegravir (CAB), which blocks the...

To view the full article, please register now for access

It's completely free